Lymphoma Product Review – Bendamustine hydrochloride in NHL and MCL

This review of the use of Bendamustine hydrochloride in the first-line therapy of indolent non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL). The review covers treatment challenges, Pharmacological properties, and clinical efficacy and safety.

Commentary has been provided by Associate Professor Judith Trotman, Director of the Clinical Research Unit at Concord Hospital who has particular expertise in the management of lymphoid malignancies.

Please login below to download this issue (PDF)